NanoString secures exclusive worldwide license to develop products for breast cancer intrinsic subtyping

December 01, 2015

"Intrinsic subtyping has entered the lexicon of breast cancer researchers and oncologists alike," said Bioclassifier co-founder Matthew Ellis, M.D., Ph.D. "Upon validation and regulatory approval, we believe this gene expression panel will become part of the standard of care for breast cancer diagnosis and treatment, and will be useful in the evaluation of all newly diagnosed breast cancer patients." Dr. Ellis also directs the Breast Cancer Program at the Washington University School of Medicine at St. Louis.

Additional co-founders of Bioclassifier include Philip Bernard, M.D., Associate Professor in the Department of Pathology at the University of Utah/Huntsman Cancer Institute, and Torsten Nielsen, M.D., Ph.D., Pathologist, BC Cancer Agency.

"Leading oncology researchers are finding that the nCounter Analysis System is the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays," said Brad Gray, President and CEO of NanoString Technologies. "We believe the NanoString Breast Cancer Intrinsic Subtyping Assay will be the first in a series of proprietary high-impact molecular diagnostic assays that we will commercialize as in vitro diagnostic products and that will be available in hospital and pathology laboratories worldwide."

The company's executive management team will be attending this week's San Antonio Breast Cancer Symposium to discuss its plans for the NanoString Breast Cancer Intrinsic Subtyping Assay with experts in the field and identify other potential partners for its future molecular diagnostics platform.

SOURCE NanoString Technologies, Inc.